Overview

Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
Fragile X Syndrome (FXS) is the most common known inherited form of mental impairment, developmental disability and autism. Minocycline is an antibiotic that has recently been used to treat the mouse model for Fragile X, and was found to reverse the structural abnormalities that are seen their brain cells. The purpose of this research study is to determine if minocycline is an effective treatment for patients with fragile X syndrome (FXS).
Phase:
N/A
Details
Lead Sponsor:
FRAXA Research Foundation
Collaborator:
Fragile X Research Foundation of Canada
Treatments:
Minocycline